Literature DB >> 34219334

Malignant struma ovarii: From case to analysis.

Sevgi Ayhan1, Fatih Kilic1, Burak Ersak1, Okan Aytekin1, Serra Akar1, Osman Turkmen1, Giray Akgul2, Atahan Toyran1, Taner Turan1, Gunsu Kimyon Comert1.   

Abstract

AIM: To evaluate the clinico-pathologic features, treatment options, prognostic factors, and survival outcomes of malignant struma ovarii based on a systematic literature review in association with our case study.
METHODS: A systematic review of the medical literature was performed to identify articles about malignant struma ovarii from January 1983 until July 2020. We evaluated 178 cases.
RESULTS: The 5-year progression-free survival (PFS) and overall survival (OS) of the entire cohort was 72.5% and 91%, respectively. In univariate analysis, younger age (<43 years), whole strumal cyst diameter >95 mm, presence of a histologic type other than papillary classic-type thyroid carcinoma within the tumor and lymphovascular space invasion were related to poor PFS. Patients who received radioactive iodine ablation (RIA) before the treatment failure had significantly higher PFS than those who did not receive RIA (94.9% vs. 64.8%, p = 0.041, respectively). In univariate analysis, PFS was significantly higher in patients who underwent gynecologic surgery followed by thyroidectomy and RIA compared with those who had surgical treatment only (94.5% vs. 64.3%, p = 0.05, respectively). However, this result could not be identified as an independent prognostic factor in multivariate analysis (p = 0.207). Younger age and absence of capsular involvement were related to significantly increased OS. Histologic type was the only independent prognostic factor for PFS (hazard ratio: 3.30, 95% confidence interval: 1.122-9.748; p = 0.030)
CONCLUSION: The most common histologic subtype was the papillary classic type. The presence of a histologic type other than the classic papillary thyroid carcinoma within the tumor was an independent adverse prognostic factor.
© 2021 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  malignant struma ovarii; ovarian cancer; papillary thyroid carcinoma; radioactive iodine; thyroidectomy

Year:  2021        PMID: 34219334     DOI: 10.1111/jog.14902

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  2 in total

1.  Survival Outcomes and Prognostic Predictors in Patients With Malignant Struma Ovarii.

Authors:  Sijian Li; Shujun Kong; Xiaoxue Wang; Xinyue Zhang; Min Yin; Jiaxin Yang
Journal:  Front Med (Lausanne)       Date:  2021-12-23

2.  Malignant struma ovarii with papillary carcinoma combined with retroperitoneal lymph node metastasis: A case report.

Authors:  Wen Xiao; Jin-Rong Zhou; Dong Chen
Journal:  World J Clin Cases       Date:  2022-03-26       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.